Investment
Features
FeesSafety
Academy
More
Pluang+

Solstice Advanced Materials agrees to settle lawsuits over its Metropolis uranium plant, focusing on community investments.

Market News
29 Sep 2026
PRNewsWire
View Source
Neutral
Solstice Advanced Materials agrees to settle lawsuits over its Metropolis uranium plant, focusing on community investments.

Solstice Advanced Materials has reached an agreement in principle to settle all litigation related to its Metropolis Works uranium conversion plant. The settlement includes significant investments in programs to improve the lives of Metropolis residents and awaits formal approval from courts and stakeholders. Solstice denies any wrongdoing but chose to settle to avoid prolonged legal costs and distractions, expecting no major impact on its business. The settlement marks a key step in resolving lawsuits dating back to 2018 involving local residents, the city, and county alleging property damage and personal injury.

Solstice Advanced Materials' settlement agreement on Metropolis Works litigation is the focus here, with Pluang market data providing context. As of Sep 30, 2026 02:51 WIB, 17 of 38 Basic Materials-sector US stocks on Pluang rose while 21 fell. Notable movers include VALE at USD 13.29 with a 31% sell / 69% buy order split, MP at USD 45.47 with 13% sell / 87% buy, and SLI at USD 1.79 with a typical hold time of 21 days.

More News

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron Technology is set to report record quarterly revenue of up to $51.33 billion, fueled by strong demand for high-bandwidth memory in the AI market. Earnings per share are expected to jump significantly to around $31.72, compared to $3.03 last ye...

Company Fundamentals
Bullish
28 minutes ago
Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma Technologies reported a smaller-than-expected loss with an EPS of -$0.08, beating analyst estimates of -$2.19, though its revenue of $48.55 million slightly missed expectations. Despite ongoing profitability challenges reflected in a negative...

Company Fundamentals
Bullish
2 hours ago
Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics has increased its full-year 2026 revenue guidance to $410-$420 million, reflecting nearly 60% growth driven by strong U.S. demand for its cancer therapy Amtagvi, which generated $91 million in Q2 sales. Analyst Joseph Pantgini...

Analyst Insights
Bullish
3 hours ago
uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure's stock fell sharply by 37% following a four-year update on its AMT-130 gene therapy for Huntington's disease, which showed reduced effectiveness from 80% at three years to 44% at four years, failing to reach statistical significance. Despite...

Market News
Bearish
3 hours ago
Grizzly Discoveries clarifies use of $2M private placement proceeds for mineral exploration and working capital

Grizzly Discoveries clarifies use of $2M private placement proceeds for mineral exploration and working capital

Grizzly Discoveries Inc. announced a non-brokered private placement aiming to raise up to $2 million. The proceeds will be used for general working capital and exploration of its mineral properties, with specific funds from certain units targeting cr...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App